Renibus

Renibus Therapeutics is a clinical-stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing breakthrough products to improve outcomes associated with renal, metabolic, and cardiac diseases. Founded in 2015 and headquartered in Southlake, Texas, Renibus is advancing two late-stage programs: Veverimer, a non-absorbed polymer in Phase 3 development for adults with chronic kidney disease and metabolic acidosis; and RBT-1, which recently completed the PROTECT Phase 3 trial for cardiac and renal protection in surgical settings. The company's leadership team brings extensive pharmaceutical commercialization experience, including prior successes at ZS Pharma (acquired by AstraZeneca for $2.7 billion), Adams Respiratory Therapeutics (acquired by Reckitt Benckiser for $2.3 billion), and multiple other biopharmaceutical ventures.